{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:28:10Z","timestamp":1786415290217,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010875","name":"Amgen Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cjco.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:43:51Z","timestamp":1776444231000},"page":"972-980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and Predictors of Lipoprotein(a) Measurement in Younger Patients Following ST-Elevation Myocardial Infarction"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-385X","authenticated-orcid":false,"given":"Negar","family":"Atefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam R.","family":"Brunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Roston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-1518","authenticated-orcid":false,"given":"Christopher B.","family":"Fordyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2026.04.003_bib1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa025142","article-title":"A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction","volume":"349","author":"Andersen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.04.003_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJM200408123510719","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"351","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.04.003_bib3","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.04.003_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022198","article-title":"Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239 234 patients during 2005 to 2018 in the United States","volume":"11","author":"Steen","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2026.04.003_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.cjco.2026.04.003_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.R071571","article-title":"Lipoprotein (a): a historical appraisal","volume":"58","author":"Kostner","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjco.2026.04.003_bib7","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjco.2026.04.003_bib8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2026.04.003_bib9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib10","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.04.003_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjco.2026.04.003_bib13","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/ph15121573","article-title":"Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy","volume":"15","author":"Sosnowska","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.cjco.2026.04.003_bib14","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib15","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib16","first-page":"867","article-title":"Clinical care for patients with elevated lipoprotein(a) level in Canada: a practical framework for screening, risk assessment, and management","volume":"42","author":"Thanassoulis","year":"2026","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib17","first-page":"411","article-title":"Lipoprotein(a) as an independent risk factor for coronary artery disease in patients below 40 years of age","volume":"52","author":"Gambhir","year":"2000","journal-title":"Indian Heart J"},{"key":"10.1016\/j.cjco.2026.04.003_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2017.12.011","article-title":"High levels of lipoprotein (a) and premature acute coronary syndrome","volume":"269","author":"Rallidis","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjco.2026.04.003_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIRCULATIONAHA.122.060667","article-title":"Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood","volume":"147","author":"Raitakari","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.04.003_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cjco.2023.11.015","article-title":"Consideration and application of lipoprotein(a) in the risk assessment of atherosclerotic cardiovascular disease risk in adults","volume":"6","author":"Yuen","year":"2023","journal-title":"CJC Open"},{"key":"10.1016\/j.cjco.2026.04.003_bib21","first-page":"1222","article-title":"Evolution and impact of a regional reperfusion system for ST-elevation myocardial infarction","volume":"32","author":"Fordyce","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cjco.2020.01.005","article-title":"Impact of patient- and system-level delays on reperfusion among patients with ST-elevation myocardial infarction","volume":"2","author":"Wenner","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.cjco.2026.04.003_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cjco.2022.11.015","article-title":"Temporal trends in reperfusion delivery and clinical outcomes following implementation of a regional STEMI protocol: a 12-year perspective","volume":"5","author":"Williams","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.cjco.2026.04.003_bib24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.04.003_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000405","article-title":"Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI","volume":"3","author":"Doost Hosseiny","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.cjco.2026.04.003_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead035","article-title":"Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up","volume":"3","author":"Ziogos","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.cjco.2026.04.003_bib27","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0735-1097(93)90213-K","article-title":"Myocardial injury: the acute phase response and lipoprotein metabolism","volume":"22","author":"Rosenson","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.04.003_bib30","first-page":"76","article-title":"Lipoprotein (a): structure, pathophysiology and clinical implications","volume":"103","author":"Maranh\u00e3o","year":"2014","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.cjco.2026.04.003_bib31","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.cjco.2025.06.021","article-title":"Implementing dyslipidemia guidelines into clinical practice following an acute coronary syndrome: challenges and opportunities for improvement","volume":"7","author":"Labinaz","year":"2025","journal-title":"CJC Open"},{"key":"10.1016\/j.cjco.2026.04.003_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON Trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjco.2026.04.003_bib33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26001502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26001502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:35:26Z","timestamp":1786412126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X26001502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589790X26001502"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2026.04.003","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and Predictors of Lipoprotein(a) Measurement in Younger Patients Following ST-Elevation Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}